Limits...
The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.

Shao X, Guo Y, Xu X, Zheng Y, Wang J, Chen Z, Huang J, Huang P, Cai J, Wang X - PLoS ONE (2015)

Bottom Line: In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041).Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002).Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

ABSTRACT

Purpose: Aromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.

Methods: Genotyping for CYP19 rs4646 variants was performed on 406 Chinese women with stage I-II and operable stage III breast cancer. Associations were evaluated between CYP19 rs4646 genotypes and disease-free survival (DFS).

Results: In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041). These differences were further demonstrated by a multivariate analysis (HR = 0.456, 95 % CI = 0.249-0.836, P = 0.011). Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002). Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).

Conclusions: The present study indicates that CYP19 rs4646 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status. The findings are novel, if confirmed, rs4646 genotypes may provide useful information for routine management in breast cancer.

No MeSH data available.


Related in: MedlinePlus

Survival curves for the postmenopausal patients.a. Disease-free survival of the postmenopausal women grouped by CYP19 rs4646 genotypes (CC vs AC vs AA). b. Disease-free survival of the postmenopausal women stratified by CYP19 rs4646 genotypes (AA vs AC + CC).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4368615&req=5

pone.0121535.g003: Survival curves for the postmenopausal patients.a. Disease-free survival of the postmenopausal women grouped by CYP19 rs4646 genotypes (CC vs AC vs AA). b. Disease-free survival of the postmenopausal women stratified by CYP19 rs4646 genotypes (AA vs AC + CC).

Mentions: In postmenopausal women, AA genotype was evident to be in relation with shorter DFS (AA versus AC versus CC: 13.7 months versus not reached versus 49.4 months, P = 0.002) (Fig. 3a). Moreover, there was significant difference in DFS between the patients with AA variant and those carrying CC or AC genotype (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95% CI = 1.432–5.313, P = 0.002) (Fig. 3b). In the Cox proportional hazards model, after adjusting for the patients features, AA variant was explored to be an independent prognostic factor for DFS (HR = 2.983, 95% CI = 1.494–5.955, P = 0.002) (Table 5).


The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.

Shao X, Guo Y, Xu X, Zheng Y, Wang J, Chen Z, Huang J, Huang P, Cai J, Wang X - PLoS ONE (2015)

Survival curves for the postmenopausal patients.a. Disease-free survival of the postmenopausal women grouped by CYP19 rs4646 genotypes (CC vs AC vs AA). b. Disease-free survival of the postmenopausal women stratified by CYP19 rs4646 genotypes (AA vs AC + CC).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4368615&req=5

pone.0121535.g003: Survival curves for the postmenopausal patients.a. Disease-free survival of the postmenopausal women grouped by CYP19 rs4646 genotypes (CC vs AC vs AA). b. Disease-free survival of the postmenopausal women stratified by CYP19 rs4646 genotypes (AA vs AC + CC).
Mentions: In postmenopausal women, AA genotype was evident to be in relation with shorter DFS (AA versus AC versus CC: 13.7 months versus not reached versus 49.4 months, P = 0.002) (Fig. 3a). Moreover, there was significant difference in DFS between the patients with AA variant and those carrying CC or AC genotype (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95% CI = 1.432–5.313, P = 0.002) (Fig. 3b). In the Cox proportional hazards model, after adjusting for the patients features, AA variant was explored to be an independent prognostic factor for DFS (HR = 2.983, 95% CI = 1.494–5.955, P = 0.002) (Table 5).

Bottom Line: In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041).Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002).Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

ABSTRACT

Purpose: Aromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.

Methods: Genotyping for CYP19 rs4646 variants was performed on 406 Chinese women with stage I-II and operable stage III breast cancer. Associations were evaluated between CYP19 rs4646 genotypes and disease-free survival (DFS).

Results: In premenopausal patients, women who are homozygous for the minor allele (AA) have a longer DFS compared with those carrying the major allele (CC or AC) (87 months versus 48.7 months; Hazard ratio (HR) = 0.56, 95 % CI = 0.318-0.985, P = 0.041). These differences were further demonstrated by a multivariate analysis (HR = 0.456, 95 % CI = 0.249-0.836, P = 0.011). Conversely, the same variant (AA) was estimated to be associated with a poorer DFS in postmenopausal women (AA versus AC or CC: 13.7 months versus 56.3 months; HR = 2.758, 95 % CI = 1.432-5.313, P = 0.002). Furthermore, the differences were confirmed by the COX proportional hazards model (HR = 2.983, 95% CI =1.494-5.955, P = 0.002).

Conclusions: The present study indicates that CYP19 rs4646 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status. The findings are novel, if confirmed, rs4646 genotypes may provide useful information for routine management in breast cancer.

No MeSH data available.


Related in: MedlinePlus